Outcome of patients in the bridging cohort. (A) Actual treatment of patients intended for CAR T-cell therapy and (B) overall survival of patients who received the intended CAR T-cell therapy after polatuzumab vedotin (pola) bridging. (C-D) Intent-to-treat-analysis with progression-free survival and overall survival of complete bridging cohort intended for CAR T-cell therapy. Survival times were calculated from the initiation of pola treatment. For the estimation of progression-free survival, data were only assessed in the efficacy-evaluable population. Three patients had no response evaluation and were excluded from the progression-free survival estimation.